Navigation Links
PharmAthene's 2nd Generation rPA Anthrax Vaccine, SparVax(TM), Completes FDA Regulatory Strategy Review
Date:7/9/2009

n of the FDA feedback to BARDA should enable the agency to recommence contract negotiations with the Company. In the meantime, development activities for the SparVax(TM) program are continuing pursuant to the Company's existing development contract for SparVax(TM), which was transferred from the National Institutes of Health to BARDA on April 1, 2009."

About SparVax(TM)

SparVax(TM) is a novel second generation recombinant protective (rPA) anthrax vaccine being developed for administration by intramuscular injection. This product employs modern vaccine technology to provide a highly purified and well characterized modern vaccine for intended use by the military and civilian Strategic National Stockpile. Phase I and Phase II clinical trials involving more than 750 healthy human subjects have been completed and showed that SparVax(TM) appears to be well tolerated and induces an immune response in humans. These studies suggest that three doses of SparVax(TM), administered several weeks apart, should be sufficient to induce protective immunity. In preclinical studies SparVax(TM) has also demonstrated the capability to protect rabbits and non-human primates against a lethal aerosol spore challenge of the anthrax Ames strain. The clinical and non-clinical studies for SparVax(TM) have been carried out under contracts with the National Institute of Allergy and Infectious Diseases and the National Institutes of Health.

About PharmAthene, Inc.

PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:

  • SparVax(TM) - a second generation recombinant protective antigen (rPA) anthrax vaccine
  • Third generation rPA anthrax vaccine
  • Valortim(R) - a full
    '/>"/>

SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. KBI Biopharma Starts Cell Line Generation Process under Vendor Network Agreement for PER.C6(R)
2. New Generation Biofuels Signs Letter of Intent with Instituto Costarricense de Electricidad (ICE) of Costa Rica
3. A-Power Energy Generation Systems Ltd. Signs a Biomass-Based DG Contract with Sanmenxia New Energy Bio-Electricity Co., Ltd.
4. Calvert Research Licenses Novel Technology to Treat Age Related Macular Degeneration from Tulane University
5. Jatrophaworld Training 2009: 2nd Generation nonfood Biofuel crops Knowledge Platform
6. Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system
7. FDA Approves Boston Scientifics Next-Generation TAXUS(R) Liberte(R) Atom(TM) Stent System
8. Angiotechs corporate partner, Boston Scientific, announces launch of third-generation TAXUS(R) Element(TM) Stent
9. Nanosys Licenses Nanowire Technology to QuantuMDx Group for Next Generation Diagnostic and Sequencing Technologies
10. City of Baltimore to Evaluate New Generation Biofuels for Use in Boiler Applications
11. SeqWright Expands into the Genetically-Targeted Therapy Field by Partnering with PharmaGenoma to Provide Next-Generation Hair Loss Treatment Genetic Testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... pacemakers may inadequately stimulate a patient,s heart while ... to the magnetic pulses mixing with the electronic ... is potentially dangerous for the patient undergoing the ... Central,s open access journal BioMedical Engineering Online ... uses a magnetic field instead of ionizing radiation ...
(Date:12/16/2009)... Martek Biosciences Corporation (Nasdaq: MATK ) ... and fiscal year ended October 31, 2009. Revenues for ... $90.4 million in the fourth quarter of fiscal 2008. ... share, for the fourth quarter of fiscal 2009, a ... diluted share, in last year,s fourth quarter. The ...
(Date:12/16/2009)... , ... Argonne, Ill. (Vocus) ... Energy’s (DOE) Argonne National Laboratory and Northwestern University, Evanston, ... in a solution, providing insights for design of bio-inspired dynamically ... million times more massive than the bacteria,” said physicist and ...
(Date:12/16/2009)... Decision Resources, one of the world,s leading research ... finds that, according to responses from surveyed dermatologists, ... interleukin inhibitors) will capture 22 percent of the ... for moderate to severe psoriasis. Among these two ... three times as much patient share as briakinumab. ...
Breaking Biology Technology:FDA researchers identify new MRI safety risk for patients with pacemakers 2Martek Announces Fourth Quarter and FY 2009 Financial Results 2Martek Announces Fourth Quarter and FY 2009 Financial Results 3Martek Announces Fourth Quarter and FY 2009 Financial Results 4Martek Announces Fourth Quarter and FY 2009 Financial Results 5Martek Announces Fourth Quarter and FY 2009 Financial Results 6Martek Announces Fourth Quarter and FY 2009 Financial Results 7Martek Announces Fourth Quarter and FY 2009 Financial Results 8Martek Announces Fourth Quarter and FY 2009 Financial Results 9Martek Announces Fourth Quarter and FY 2009 Financial Results 10Martek Announces Fourth Quarter and FY 2009 Financial Results 11Martek Announces Fourth Quarter and FY 2009 Financial Results 12Martek Announces Fourth Quarter and FY 2009 Financial Results 13Martek Announces Fourth Quarter and FY 2009 Financial Results 14Argonne Scientists Use Bacteria to Power Simple Machines 2Argonne Scientists Use Bacteria to Power Simple Machines 3In 2012, Stelara and Briakinumab Will Capture 22 Percent of the Biologics Share in the Moderate to Severe Psoriasis Drug Market 2In 2012, Stelara and Briakinumab Will Capture 22 Percent of the Biologics Share in the Moderate to Severe Psoriasis Drug Market 3
... Pharmaceuticals,Inc. (Nasdaq: AMLN ) will be presenting at ... FL on Thursday, May 1,2008 at 9:20 a.m. ET ... Executive Officer of Amylin Pharmaceuticals, will be providing a,corporate ... be webcast, and a,recording will be made available following ...
... America (Nasdaq: DCAI ) announced today that it ... 7, 2008, after the close of the,market. The company ... first quarter 2008 earnings release the following morning, May ... participating in the May 8, 2008 conference call,may dial ...
... Congenital Heart Disease Database and, the Further Transition ... ... April 25 VentriPoint(TM) Diagnostics,Ltd. (TSX: VPT) today announced ... with the University of Washington to,collaborate on projects that ...
Other Biology Technology:Dialysis Corporation of America Announces First Quarter 2008 Earnings Release Date 2VentriPoint, University of Washington Sign Research and Technology Development Agreement 2
(Date:12/16/2009)... Calif. and PALM HARBOR, Fla., Dec. 2 ... Bulletin Board: CICI), a leading supplier of ... in the financial industry* and the recognized ... Systems Inc. ("Docubase"), a leading International Electronic ... that they have entered an agreement to ...
(Date:12/16/2009)... -- BIO-key International, Inc. (OTC Bulletin Board: ... solutions, today announced that SC Magazine, one ... named BIO-key International the 2009 Innovator of ... Biometrics. ,, (Logo: http://www.newscom.com/cgi-bin/prnh/20050509/BIOKEYLOGO ) ... SC Magazine, "Biometric providers have been trying ...
(Date:12/15/2009)... soon as babies are born, they are susceptible to ... up to a month, their immune systems aren,t adequately ... minor, they can lead to serious problems if left ... Missouri researchers have pinpointed a group of depleted white ... , "We,re trying to improve the immune system of ...
Breaking Biology News(10 mins):CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 2CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 3CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 4BIO-key(R) Selected as 2009 Industry Innovator in Biometrics by SC Magazine 2BIO-key(R) Selected as 2009 Industry Innovator in Biometrics by SC Magazine 3Researchers work on vaccine to improve immune system in newborns 2New nanocrystalline diamond probes overcome wear 14803 1New nanocrystalline diamond probes overcome wear 14803 2Speedus Corp Names Stephen X Graham to Board of Directors 61195 1Speedus Corp Names Stephen X Graham to Board of Directors 61195 2SC Johnson Makes Commitment to Clinton Global Initiative 61192 1SC Johnson Makes Commitment to Clinton Global Initiative 61192 2SC Johnson Makes Commitment to Clinton Global Initiative 61192 3
... dramatic reduction in the impact of malaria is in prospect ... Guinea early next year. Success in the trial would open ... with this debilitating and often fatal disease - over 500,000,000 ... Medical Research is collaborating with the Papua New Guinea Institute ...
... Francisco VA Medical Center (SFVAMC) and the University of ... with lymphocytic bronchitis, which is thought to lead to ... failure of transplanted lungs. , The researchers hope their ... more accurate standard test for chronic lung rejection, as ...
... number of living Florida panthers has grown from a previously ... of a controversial breeding effort to improve the genetic health ... assessment. , Hybrid kittens born to panthers brought into the ... of becoming adults as do purebred ones," reports a paper ...
Other Biology News:Old drug, new tricks: Prospects for slashing the impact of malaria 2Researchers identify genes associated with lung transplant rejection 2Research suggests fitness of Florida panthers improved by limited breeding with Texas animals 2Research suggests fitness of Florida panthers improved by limited breeding with Texas animals 3
... Works fast and effectively in tubes and 96 ... simple, one tube, one and a half spin ... clean up or concentrate any type of double ... primer dimers or dNTPs (labelled or unlabelled). It ...
... 96 x 0.2 ml tubes or a ... a thumbwheel to adjust height and pressure ... cycling. Peltier heat pumps produce uniform, accurate ... of up to 1.4 degrees C per ...
... The DTX Series Multimode Detectors ... a variety of application and automation ... and absorbance measurements on the same ... as standalone instruments or can be ...
Sf21 Insect Cells (Live) in Max-XP Medium...
Biology Products: